In a study published online in the British journal Nature, the early use of the antiviral drug Remdesivir to treat red-tailed monkeys with the new coronavirus helped to reduce virus levels and prevent red-tailed monkeys from breaking out. Rui Dexi Feng (Rui Dexi Feng) is an antiviral drug developed by Giliado Technology in the United States, which is planned to be used to treat Ebola hemorrhagic fever and Middle East respiratory syndrome. The US Food and Drug Administration has previously issued an emergency license, which allows US medical institutions to "emergency use" emdecibir when treating critically ill patients with new coronary artery disease.
In order to evaluate the effectiveness of emdesivir, a research team led by scholars from the National Institutes of Health divided the red-tailed monkeys infected with the new coronavirus into two groups of six. One group received rebedil treatment 12 hours after being infected with the virus. This is close to the peak period of viral replication in the lungs, and treatment is performed every 24 hours after infection for 6 days. Studies have shown that 12 hours after receiving the first treatment, the airway virus levels of the red lizards in the treatment group were lower, about 1% of the control group. Three days after infection, the red lizard was no longer detected in the treatment group. Virus, but 4 out of 6 controlled red lizards can still detect the virus. The research team found that compared with the control group, the red lizards in the treatment group had no signs of respiratory disease, had less lung damage, and lower respiratory tract viruses, but no reduction in virus excretion was observed. Say so. Researchers have shown that the dose of Redivir used by red-throated monkeys is the same as that used by humans, but because red-throated monkeys usually have mild symptoms after being infected with the new coronavirus, that is, humans. It is difficult to directly reproduce the treatment point.